HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Boer, W. I. Search for Related Content PubMed PubMed Citation Articles by de Boer, W. I.

Cytokines and Therapy in COPD^*

A Promising Combination?

^* From the Department of Pulmonary Medicine, Erasmus University, Rotterdam, The Netherlands.

Correspondence to: W. I. de Boer, PhD, Department of Pulmonary Medicine, Erasmus University, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands; e-mail: deboer.pim{at}hetnet.nl

COPD is a major health problem, with patients showing a progressively declining, largely irreversible, change in lung function. This is associated with chronic airways inflammation and structural remodeling, including loss of alveolar walls, and goblet cell metaplasia with mucus hypersecretion. Inflammatory cells may contribute to the airway remodeling via secretion of proteases, fibrotic or mitogenic growth factors, and cytokines. In turn, airway remodeling may contribute to the clinical symptoms of COPD. Currently available therapies are directed to improvement of clinical symptoms and reduction of the airways inflammation. The commonly used glucocorticosteroids are expected to reduce the inflammation by acting on kinases or transcription factors necessary for expression of pro-inflammatory cytokines or chemokines. However, several long-term and short-term studies showed that glucocorticosteroids are rather ineffective in improving lung function and reducing the airway inflammation in patients with COPD. New therapeutic strategies may reduce the inflammation and alleviate the clinical symptoms of COPD. Tumor necrosis factor-, interleukin-8, and monocyte chemoattractant protein-1 are important chemotactic proteins for macrophages and neutrophils, the predominant inflammatory cells associated with COPD. As lung levels of these cytokines are higher in COPD compared to non-COPD patients, they may represent targets for novel therapies.

Key Words: antagonists • chemokines • COPD • cytokines • interleukin-8 • monocyte chemoattractant protein-1 • receptors • therapy • tumor necrosis factor

This article has been cited by other articles:

				E. Reyes, A. Prieto, A. de la Hera, P. de Lucas, R. Alvarez-Sala, J. L. Alvarez-Sala, and M. Alvarez-Mon Treatment With AM3 Restores Defective T-Cell Function in COPD Patients Chest, March 1, 2006; 129(3): 527 - 535. [Abstract] [Full Text] [PDF]

				K.-i. Inoue, H. Takano, R. Yanagisawa, T. Yoshikawa, D. A. Mahler, and G. M. Bell Interleukin-8 Neutralization for COPD Chest, July 1, 2005; 128(1): 464 - 465. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]

				J Yarden, D Radojkovic, K De Boeck, M Macek Jr, D Zemkova, V Vavrova, R Vlietinck, J-J Cassiman, and H Cuppens Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype Thorax, April 1, 2005; 60(4): 320 - 325. [Abstract] [Full Text] [PDF]

				S. Fuke, T. Betsuyaku, Y. Nasuhara, T. Morikawa, H. Katoh, and M. Nishimura Chemokines in Bronchiolar Epithelium in the Development of Chronic Obstructive Pulmonary Disease Am. J. Respir. Cell Mol. Biol., October 1, 2004; 31(4): 405 - 412. [Abstract] [Full Text] [PDF]

				D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study Chest, September 1, 2004; 126(3): 926 - 934. [Abstract] [Full Text] [PDF]

				M. J. Ruddy, F. Shen, J. B. Smith, A. Sharma, and S. L. Gaffen Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment J. Leukoc. Biol., July 1, 2004; 76(1): 135 - 144. [Abstract] [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]